Moderna’s oncology pipeline also includes a Merck-partnered personalized cancer vaccine called intismeran autogene or ...
Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...
Moderna (MRNA) and Merck (MRK) reported data regarding their cutting-edge mRNA-based skin cancer regimen that includes the former's cancer vaccine, MRNA-4157. The companies recently reported promising ...
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...
A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...
TipRanks on MSN
Moderna up 8% after STAT report on buyout potential
Shares of Moderna (MRNA) are up $1.97, or 8% to $26.67 in morning trading. Published first on TheFly – the ultimate source for real-time, ...
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...
No sooner did Moderna (MRNA) and Merck & Co. (MRK) announce additional positive data for their cancer vaccine candidate, a messenger RNA (mRNA)-based individualized neoantigen therapy (INT), than ...
Vaccine experts told STAT that the data Moderna released May 18 from its phase I vaccine trial isn’t enough to show whether or not the vaccine will be effective. Moderna released data from an early ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback